Clinical Trial

Canakinumab for the Treatment of Postprandial Hypoglycemia

Study acronym: CanpHy
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated January 29, 2025 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of this randomized trial is to test whether a treatment with canakinumab is superior to placebo in patients with postprandial hypoglycemia after bariatric surgery, that is if it improves health related quality of life (mentally or physically) or reduces the risk of hypoglycemic events.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-05-30; most recent amendment 2025-01-27.
Trial Details
NCT Number NCT05401578
Lead Sponsor University Hospital, Basel, Switzerland
Conditions Postprandial Hypoglycemia
Enrollment 56 participants
Start Date 2023-04-17
Primary Completion 2026-05-31 (estimated)
Study Completion 2026-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-29